Arduino Samorì

Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma

M. Offidani, R. Rizzi, P. Leoni, 2011, Annals of Hematology.

Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry.

P. Galieni, F. Alesiani, M. Burattini, 2012, Clinical lymphoma, myeloma & leukemia.

ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma

P. Galieni, F. Alesiani, M. Burattini, 2010, European journal of haematology.

Thalidomide‐dexamethasone versus Interferon‐alpha‐dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study

P. Galieni, F. Alesiani, M. Burattini, 2009, British journal of haematology.

Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide

P. Galieni, F. Alesiani, G. Visani, 2011, Leukemia & lymphoma.

Fatal Necrotizing Angiotropic Epstein–Barr Virus-negative Large B-cell Lymphoma

S. Pileri, E. Sabattini, G. Goteri, 2014, Medicine.